Mario Negri Institute For Pharmacological Research

This trial tests whether obinutuzumab, a next-generation antibody, can help people with membranous nephropathy—a kidney disease that causes protein leakage and swelling—who haven't responded well to the standard drug rituximab or who can't take it due to allergic reactions. About…

This phase 2 trial tests felzartamab (MOR202), an antibody that targets CD38 on plasma cells, in people with membranous nephropathy who did not improve with rituximab or similar therapies. The goal is to reduce protein leakage in urine and achieve remission of nephrotic syndrome.…

This phase 2 study tested whether adding pioglitazone (a diabetes drug) to trabectedin (a chemotherapy) could help shrink or control liposarcoma, a rare cancer of fat tissue. The study included 10 patients whose tumors had stopped growing but not shrunk with trabectedin alone. Re…

This completed study tested whether school-based programs involving families could help prevent childhood obesity. Researchers worked with 226 children aged 6-11 to measure their eating habits, physical activity, and family lifestyles. The goal was to see if these programs are pr…

This study examined 10 people with autosomal dominant polycystic kidney disease (ADPKD) to see if a specific deletion in the PKD2 gene is shared among families in the Bergamo area. Researchers interviewed participants and built family trees to understand how the gene change affec…

This study looks at blood samples from 48 people with membranous nephropathy, a kidney disease. Researchers used a special test to measure immune cells (B cells) that target a protein called PLA2R. The goal is to see how these cells change after treatment with B-cell depleting dr…